These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15546153)

  • 21. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
    Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
    Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatotoxicity of statins and other lipid-lowering agents.
    Björnsson ES
    Liver Int; 2017 Feb; 37(2):173-178. PubMed ID: 27860156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
    You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
    Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiologic evidence of relationships between reproductive and child health outcomes and environmental chemical contaminants.
    Wigle DT; Arbuckle TE; Turner MC; Bérubé A; Yang Q; Liu S; Krewski D
    J Toxicol Environ Health B Crit Rev; 2008 May; 11(5-6):373-517. PubMed ID: 18470797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells.
    Sokalska A; Hawkins AB; Yamaguchi T; Duleba AJ
    J Assist Reprod Genet; 2019 Mar; 36(3):535-541. PubMed ID: 30554393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study.
    Quinn KL; Macdonald EM; Mamdani MM; Diong C; Juurlink DN;
    Drug Saf; 2017 Oct; 40(10):887-893. PubMed ID: 28620871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA; Sinclair SM
    Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.
    Kobayashi M; Chisaki I; Narumi K; Hidaka K; Kagawa T; Itagaki S; Hirano T; Iseki K
    Life Sci; 2008 Apr; 82(17-18):969-75. PubMed ID: 18402982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.
    Hennekens CH
    Am J Cardiovasc Drugs; 2008; 8(3):155-60. PubMed ID: 18533736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.